To determine whether sustained MYC expression drives platinum resistance in vivo we took advantage of a mouse model of SCLC driven by the loss of Rb1 and Trp53 combined with sustained expression of MYC exclusively in neuroendocrince cells of the lung (RPM mice) [15]. This evidence concerns the gene TP53 and small cell lung carcinoma.